Richter-Helm BioLogics has announced a technological breakthrough in the field of purification of antibody fragments from an E coli expression system.
The company has finalized the downstream process for Phase III clinical trial material using Second Generation Expanded Bed Adsorption (EBA) technology developed by the Danish biotech company, Upfront Chromatography A/S.
The former has discovered significant advantages of the EBA technology over alternative chromatographic methods. A 60 percent increase in yield was observed using direct capture. The simplified process is less likely to cause processing problems.
The processing time to take product from homogenate to clarified, partially purified material was reduced to one working day, decreasing the possibility of product degradation.
The volume of buffers required to perform clarification and capture was reduced significantly, effecting cost of manufacture.
Share this: 
Del.icio.us |
Email This | 
Printer Friendly
